ML372 inhibits ubiquitination of survival motor neuron (SMN) protein, enhances SMN protein stability without affecting mRNA expression, and ameliorates spinal muscular atrophy (SMA) in mice; it exhibits brain permeability with reasonable in vivo exposure and half-life.